STAT

OCTOBER 28, 2022

There are increasing signs that flu season is off to a very early start in parts of the United States, with the cumulative hospitalization rate higher than it has been at this point in the fall for more than a decade, the Centers for Disease Control and Prevention reported Friday. In its weekly FluView report , the CDC estimated that there have already been 880,000 influenza illnesses, 6,900 flu hospitalizations, and 360 deaths caused by flu this season, which started at the beginning of October

Hospitals 315

Hospitals 315

PharmaVoice

OCTOBER 25, 2022

The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

265

265

ID Stewardship

OCTOBER 27, 2022

In this article an infectious diseases pharmacist discusses antibiotic myths. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 27 October 2022. Have you ever seen the show MythBusters on the Discovery Channel? Well this blog post is not nearly as cool as that show, but it may be a fun read at least! Here are 15 antibiotic myths to beware… Myth 1: Stopping antibiotic courses early leads to antibiotic resistance.

Labelling 145

Labelling 145

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Considering the low chances of success, with only 10% of drug candidates making it into clinical development, pharma companies must prevent the increased erosion of profit margins.

Compounding 124

Compounding 124

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

OCTOBER 28, 2022

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned. One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT.

Documentation 302

Documentation Drug Development 302

PharmaVoice

OCTOBER 26, 2022

The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.

265

265

pharmaphorum

OCTOBER 28, 2022

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and ensure global pharmaceutical and biotech organisations continue to prioritise the UK as a launch destination. Join us on Wednesday 23rd November at 12:30 GMT / 13:30 CET / 7:30 am EST as the panel discuss how the Innovative Medicines Fund works, what the implications are for industry organisations in securing fu

Biosimilars 121

Biosimilars 121

STAT

OCTOBER 26, 2022

Who gets better medical care in the United States: “addicts,” or “people with substance use disorders”? The terms, of course, mean functionally the same thing. But in the field of addiction medicine, the question presents something of a crisis. Even as drugs and alcohol claim 200,000 lives each year, many who seek addiction treatment are greeted by the harsh, stigmatizing labels that many Americans don’t think twice about: Words like addict, alcoholic, junkie,

Labelling 292

Labelling 292

PharmaVoice

OCTOBER 25, 2022

The company's head of U.S. and Canadian operations explains how the company is evolving its game plan after 100 years in the insulin space.

265

265

European Pharmaceutical Review

OCTOBER 28, 2022

Biotech firm Omega Therapeutics, Inc. revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 targets c-Myc (MYC), a key oncogene and master transcription factor that regulates cell proliferation, differentiation and apoptosis and plays a major role in over half of all human cancers.

111

111

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

pharmaphorum

OCTOBER 25, 2022

Novartis has abandoned development of its drug to treat presbyopia, a common age-related loss of near distance vision, after it failed a phase 2b trial. The eyedrop formulation of UNR844 (lipoic acid/choline ester chloride) was acquired as part of the group’s buyout of privately-held ophthalmology biotech Encore Vision for $375 million upfront in 2017, and was designed to work by restoring the elasticity of the eye’s lens that declines with age.

118

118

STAT

OCTOBER 25, 2022

As MacArthur Foundation fellow Jennifer Richeson noted in The Atlantic in 2020, Americans love to perpetuate narratives of racial progress , regardless of whether that narrative is aligned with reality. We saw this in a recent New York Times essay that claimed the change in Covid-19 death rates is a laudable example of the U.S. overcoming racial injustice.

Vaccines 286

Vaccines 286

PharmaVoice

OCTOBER 26, 2022

The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

Drug Development 265

Drug Development 265

European Pharmaceutical Review

OCTOBER 25, 2022

AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) combination therapy has been approved in the US for adult patients with unresectable hepatocellular carcinoma (HCC). Phase III trial results found that three years post-treatment, 31 percent of patients given the drug combination were still alive. The statistic for those just offered sorafenib was 20 percent.

111

111

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

The Thyroid Pharmacist

OCTOBER 28, 2022

When I was searching for answers on how to get my Hashimoto’s into remission and feel like myself again after so many years of frustrating symptoms, I started by analyzing my health timeline, and then investing in functional medicine testing. I have shared my full health timeline in my book Hashimoto’s: The Root Cause , but some notable triggers include recurrent Strep throat infections, recurrent UTIs, and of course recurrent antibiotics for both!

Health and Personal Care Stores 105

Health and Personal Care Stores Immunization Immunity Grocery Stores 105

STAT

OCTOBER 27, 2022

As an oncologist and a leader at a national cancer organization, I’ve watched countless families celebrate the incredible news that their child has defeated a pediatric cancer. But I often don’t have the heart — at least not right away — to tell them what’s coming next: a lifetime of doctor’s visits, health issues, and stress, much of it related to the treatments that were used to ensure their child’s survival.

274

274

PharmaVoice

OCTOBER 27, 2022

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

246

246

European Pharmaceutical Review

OCTOBER 27, 2022

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) has released new data on the US bioscience industry, indicating it was valued at $2.9 trillion dollars in 2021. The report also found that in 2021, the US industry employed 2.1 million people in over 127,000 businesses. The report , developed in partnership by TEConomy Partners and BIO, is the tenth in a biennial series that assesses the state of the US bioscience industry and its innovation s

Pharmaceutical Manufacturing 105

Pharmaceutical Manufacturing Vaccines Compounding 105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). There are options in the future to possibly apply the worldwide research and development (R&D), manufacturing and marketing expertise of Astellas in gene therapy to AAV gene therapy development programmes of Taysha for genetic ailments of the central nervous system (CNS).

105

105

STAT

OCTOBER 25, 2022

Over the past few weeks, cases of flu have begun to creep up across the U.S., with spikes in the southeast and south central part of the country. Flu hospitalizations are also on the rise. According to the Centers for Disease Control and Prevention’s influenza tracking team, all signs point to an earlier than usual flu season. At the same time, hospitals across the country are filling up with children who’ve contracted RSV — a virus that causes common cold-like symptoms that

Hospitals 261

Hospitals Vaccines 261

PharmaVoice

OCTOBER 28, 2022

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

245

245

European Pharmaceutical Review

OCTOBER 26, 2022

Some 70-80% of antibody drug conjugate (ADC) developers outsource their operations to contract development and manufacturing organisations (CDMOs) to yield cost savings opportunities, according to a recent market report. Manufacturing agreements emerged as the most popular type of partnership model for ADC developers, adopted by 18 percent of stakeholders, followed by product development agreements (16 percent) and research agreements (15 percent), the market research found. .

105

105

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

OCTOBER 26, 2022

Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84 million) fine levied by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. The two drugmakers were fined in July, after the CMA upheld a preliminary judgment that Pfizer and Flynn had abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to swell from around £2 million a year in 2012 to £50 million the following y

Drug Pricing 105

Drug Pricing 105

STAT

OCTOBER 27, 2022

Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies. Over the past week, Areva Pharmaceuticals began marketing vials of fludarabine at a wholesale price of $2,736, a much steeper cost than the $272 charged for the same dosage by Fresenius Kabi and the $109 price

Dosage 261

Dosage Drug Pricing 261

PharmaVoice

OCTOBER 24, 2022

In a recent study, 50% of healthcare consumers reported that a bad digital experience with their provider ruined the entire experience, while 39% felt that a good digital interaction had a positive influence.

187

187

Pharma Times

OCTOBER 25, 2022

Millions will be invited to join the programme to ‘prevent, detect and treat’ diseases

135

135

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

OCTOBER 25, 2022

AstraZeneca’s IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker’s efforts to expand its label keep running into difficulties. Earlier this year, the FDA rejected AZ’s application for Fasenra (benralizumab) as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) with a request for more data.

Labelling 109

Labelling 109

STAT

OCTOBER 27, 2022

The crisis of opioid overdose deaths that sparked the multitude of lawsuits leading to a historic settlement continues to rage, with overdose deaths at an all-time high despite heightened national awareness and more resources than ever dedicated to treatment and overdose prevention. The persistence of this crisis underscores the dire need for well-informed and sustainable solutions that work — and funding for them.

254

254

PharmaVoice

OCTOBER 24, 2022

In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.

Biosimilars 204

Biosimilars 204

Pharma Times

OCTOBER 27, 2022

UK only places 11th in terms of total R&D investment as a percentage of GDP

143

143

PhRMA

OCTOBER 26, 2022

A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers.

106

106